Posted by Michael Wonder on 01 Jun 2020
Menlo Therapeutics receives FDA approval of Zilxi (minocycline) 1.5 % topical foam, the first topical minocycline treatment for rosacea
29 May 2020 - Zilxi now approved for inflammatory lesions of rosacea in adults.
Menlo Therapeutics today announced that the U.S. FDA has approved Zilxi (minocycline) 1.5 % topical foam for the treatment of inflammatory lesions of rosacea in adults.
Zilxi, developed as FMX103 by Menlo’s wholly owned subsidiary Foamix Pharmaceuticals, is the first minocycline product of any kind to be approved by the FDA for use in rosacea.
